<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02215772</url>
  </required_header>
  <id_info>
    <org_study_id>1246.14</org_study_id>
    <nct_id>NCT02215772</nct_id>
  </id_info>
  <brief_title>Metabolism and Pharmacokinetics of [14C]-BI 44370 BS Administered as an Oral Solution in Healthy Male Volunteers</brief_title>
  <official_title>A Phase I Trial to Investigate the Metabolism and Pharmacokinetics of an Open Label Single Dose of 200 mg [14C]-BI 44370 BS Administered as an Oral Solution in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to investigate the basic pharmacokinetics of BI 44370 BS, its metabolite CD 10419 BS,
      and 14C-radioactivity including mass balance, excretion pathways, and metabolism following a
      single oral administration of 200 mg [14C]BI 44370 BS to healthy male volunteers and to
      evaluate safety and tolerability following a single oral administration of 200 mg [14C]BI
      44370 BS to healthy male volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Individual time course profiles of [14C]-radioactivity in whole blood, plasma, urine</measure>
    <time_frame>up to day 15</time_frame>
    <description>in nmoleq/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual time course profiles of [14C]-radioactivity in faeces</measure>
    <time_frame>up to day 15</time_frame>
    <description>in nmoleq/kg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual time course profiles of BI 44370 BS (and its glucuronide CD 10419 BS) in plasma and urine</measure>
    <time_frame>up to 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and extent of excretion mass balance based on the total radioactivity in urine and faeces</measure>
    <time_frame>up to 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cblood cells/Cplasma ratio of [14C]-radioactivity</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cblood /Cplasma ratio of [14C]-radioactivity</measure>
    <time_frame>up to 144 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of major metabolites in plasma, urine, and faeces</measure>
    <time_frame>up to day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum concentration of the analyte(s) in plasma)</measure>
    <time_frame>up to 144 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax (time from dosing to the maximum concentration of the analyte(s) in plasma)</measure>
    <time_frame>up to 144 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte(s) in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>up to 144 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf. (area under the concentration-time curve of the analyte(s) in plasma over the time interval from 0 to infinity)</measure>
    <time_frame>up to 144 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>λz (terminal rate constant in plasma)</measure>
    <time_frame>up to 144 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 (terminal half-life of the analyte(s) in plasma)</measure>
    <time_frame>up to 144 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MRTpo (mean residence time of the analyte(s) in the body after oral administration)</measure>
    <time_frame>up to 144 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F (total clearance of the analyte in plasma after oral administration)</measure>
    <time_frame>up to 144 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F (apparent volume of distribution during the terminal phase λz following an oral dose)</measure>
    <time_frame>up to 144 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ae0-tz (amount of analyte that is eliminated in urine within the time interval zero to tz, additionally excretion within each sampling interval will be calculated)</measure>
    <time_frame>up to 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fe0-tz (fraction of analyte excreted in urine within the time interval zero to tz in % of dose, additionally excretion within each sampling interval will be calculated)</measure>
    <time_frame>up to 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aefaeces,0-tz (amount of analyte excreted in faeces within the time interval zero to tz, additionally excretion within each sampling interval will be calculated)</measure>
    <time_frame>up to 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fefaeces,0-tz (fraction of analyte excreted in faeces within the time interval zero to tz in % of dose, additionally excretion within each sampling interval will be calculated)</measure>
    <time_frame>up to 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CLR,t1-t2 (renal clearance of analyte from the within the time interval t1 to t2)</measure>
    <time_frame>up to 15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically relevant findings in vital signs</measure>
    <time_frame>up to 23 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically relevant findings in 12-lead electrocardiogram (ECG)</measure>
    <time_frame>up to 23 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically relevant laboratory findings</measure>
    <time_frame>up to 23 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to up to 44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of global tolerability on a 4-point scale</measure>
    <time_frame>day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 44370 BS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg containing 2.43 megabecquerel (MBq) 14C-radioactivity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 44370 BS</intervention_name>
    <arm_group_label>BI 44370 BS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males according to the following criteria based upon a complete medical
             history, including the physical examination, vital signs (blood pressure (BP), pulse
             rate (PR)), 12-lead ECG, clinical laboratory tests

          -  Age ≥18 and ≤65 years

          -  Body mass index (BMI) ≥18.0 and BMI ≤30.0 kg/m2

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and the local legislation

        Exclusion Criteria:

          -  Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance

          -  Any evidence of a clinically relevant concomitant disease

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  History of relevant orthostatic hypotension, fainting spells or blackouts

          -  Chronic, or relevant acute infections

          -  History of relevant allergy/hypersensitivity (including allergy to study drug or its
             excipients)

          -  Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial

          -  Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 10 days prior to administration
             until after the last sample from Visit 2 is collected

          -  Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

          -  Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)

          -  Inability to refrain from smoking during the stay in the trial centre

          -  Alcohol abuse (more than on average 2 units of alcoholic beverages per day or more
             than 14 units per week (1 unit equals 1 pint [285 mL] of beer or lager, 1 glass [125
             mL] of wine, 25 mL shot of 40% spirit))

          -  Drug abuse

          -  Blood donation (more than 100 mL within 60 days prior to study drug administration or
             during the trial)

          -  Excessive physical activities (within one week prior to administration or during the
             trial until follow-up examination)

          -  Any laboratory value outside the reference range that is of clinical relevance

          -  Inability to comply with dietary regimen of study centre

          -  A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
             QTc interval &gt;450 ms)

          -  Veins unsuitable for blood sampling

          -  PR interval &gt;220 ms or QRS interval &gt;120 ms

          -  Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays of
             thorax and bony skeleton (excluding spinal column)), during work or during
             participation in a medical trial in the previous year

          -  Irregular defecation pattern (less than once per 2 days)

          -  Not willing to use adequate contraception (condoms use plus another form of
             contraception e.g. spermicide, oral contraceptive taken by female partner,
             sterilisation, intrauterine device) during the whole study period from the time of the
             first intake of study drug until three months after the last intake
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2014</study_first_submitted>
  <study_first_submitted_qc>August 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2014</study_first_posted>
  <last_update_submitted>August 12, 2014</last_update_submitted>
  <last_update_submitted_qc>August 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

